# Phase 01 validation

Status: Passed on 2026-08-23

## Automated checks

- [x] `npm run lint`
- [x] `npm run build`

Lint completes with five pre-existing warnings in `carousel.tsx`, `form.tsx`, and `reports.tsx`; Phase 01 files introduce no lint errors or warnings. The production build compiled, type-checked, generated 18 static pages, and emitted only the same warnings.

## Product regression

- [x] Homepage still lists all current products.
- [x] `/catalog` still lists all current products.
- [x] `/serum` still lists the three current serums.
- [x] Existing product URLs render the correct content and canonical.
- [x] Wildberries outbound links remain correct.

The existing localhost server returned HTTP 200 for `/`, `/catalog`, `/serum`, all three product URLs, `/about`, `/contacts`, and `/sitemap.xml`. Live HTML and generated static HTML contain the existing product slugs, canonical URLs, Wildberries IDs, accepted product copy, and sitemap entries.

## New model checks

- [x] Brand and category identifiers are stable and typed.
- [x] Marketplace links are optional by marketplace.
- [x] Multiple marketplace actions render without layout or accessibility problems.
- [x] Outbound analytics include the approved dimensions and no personal data.

Contract checks covered a draft with zero destinations, a published product with both Wildberries and Ozon, rejection of a published product with zero destinations, invalid marketplace hosts, marketplace URL preparation, safe campaign normalization and omission, platform goal names, complete payload delivery, and navigation-safe analytics failures.

A temporary two-destination build fixture confirmed that Wildberries and Ozon actions render in global order; the fixture was removed before the final build. Browser checks at 1280 px and 390 px found no horizontal overflow, confirmed accessible product image labels and marketplace links, and reported no console errors. Empty trichologist and contact forms displayed client validation errors without navigation or sending customer data.

## Exit approval

- **Reviewed by:** Codex implementation validation
- **Review date:** 2026-08-23
- **Result:** Passed
- **Notes:** Phase 02 is technically ready but remains blocked by authoritative application and precaution wording for both creams.
